Skip to main content
SpringerLink
Log in

Murine Models of Eosinophilic Leukemia: A Model of FIP1L1-PDGFRα Initiated Chronic Eosinophilic Leukemia/Systemic Mastocytosis

  • Protocol
  • First Online:
Eosinophils

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1178))

Abstract

Chronic eosinophilic leukemia (CEL) was distinguished from hypereosinophilic syndrome (HES) in the 2001 World Health Organization (WHO) criteria. Subsequently, the FIP1L1-PDGFRα (F/P) fusion tyrosine kinase was identified in patients with HES and found to be the most common clonal defect in CEL and the second most frequent mutation in systemic mastocytosis (SM). Introduction of F/P into bone marrow hematopoietic stem cells and progenitors has been used to establish murine models of F/P-myeloproliferative neoplasm and F/P–CEL. IL-5 overexpression and introduction of F/P is required to develop murine CEL. This F/P-CEL model is thought to be an accurate model of the clinical disease. Here we describe the method of F/P-CEL/SM model development and assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. IARC Press, Lyon, France

    Google Scholar 

  2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214

    Article  CAS  PubMed  Google Scholar 

  3. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 100:7830–7835. doi:10.1073/pnas.0932698100, 0932698100 [pii]

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Gotlib J (2012) World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:903–914. doi:10.1002/ajh.23293

    Article  PubMed  Google Scholar 

  5. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG (2003) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3: 459–469

    Article  CAS  PubMed  Google Scholar 

  6. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E, Drupt F, Demarty AL, Roumier AS, Gardembas M, Dib M, Philippe N, Cambier N, Barete S, Libersa C, Bletry O, Hatron PY, Quesnel B, Rose C, Maloum K, Blanchet O, Fenaux P, Prin L, Preudhomme C (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19:792–798

    Article  CAS  PubMed  Google Scholar 

  7. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103: 2939–2941

    Article  CAS  PubMed  Google Scholar 

  8. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA (2006) The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107: 4071–4079

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, Williams DA, Cancelas JA, Rothenberg ME (2008) FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 112: 2500–2507

    Article  CAS  PubMed  Google Scholar 

  10. Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y (2009) FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284:7719–7732. doi:10.1074/jbc.M807489200, M807489200 [pii]

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Li B, Zhang G, Li C, He D, Li X, Zhang C, Tang F, Deng X, Lu J, Tang Y, Li R, Chen Z, Duan C (2012) Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. PLoS ONE 7: e34912. doi 10.1371/journal.pone.0034912. PONE-D-11-17321 [pii]

    Google Scholar 

  12. Mishra A, Hogan SP, Brandt EB, Rothenberg ME (2002) IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 168:2464–2469

    Article  CAS  PubMed  Google Scholar 

  13. Williams DA, Tao W, Yang F, Kim C, Gu Y, Mansfield P, Levine JE, Petryniak B, Derrow CW, Harris C, Jia B, Zheng Y, Ambruso DR, Lowe JB, Atkinson SJ, Dinauer MC, Boxer L (2000) Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 96:1646–1654

    CAS  PubMed  Google Scholar 

  14. Discombe G (1946) Criteria of eosinophilia. Lancet 1:195

    Article  CAS  PubMed  Google Scholar 

  15. Yang S, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, Xu L, Nolan GP, Nabel GJ (1999) Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 10:123–132. doi:10.1089/10430349950019255

    Article  CAS  PubMed  Google Scholar 

  16. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA (2005) Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med 11:886–891, doi: nm1274 [pii]. 10.1038/nm1274

    Article  CAS  PubMed  Google Scholar 

  17. Minns LA, Menard LC, Foureau DM, Darche S, Ronet C, Mielcarz DW, Buzoni-Gatel D, Kasper LH (2006) TLR9 is required for the gut-associated lymphoid tissue response following oral infection of Toxoplasma gondii. J Immunol 176:7589–7597, doi: 176/12/7589 [pii]

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

A Part of this project was supported by Research on Intractable Diseases, Health and Labour Sciences research grants from the Ministry of Health, Labour and Welfare of Japan and by a Grant-in-Aid for Scientific Research C from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Authors and Affiliations

  1. Division of Allergy and Immunology, Gunma Children’s Medical Center, 779 Shimohakoda Hokkitsu, Shibukawa, Gunma, 377-8577, Japan

    Yoshiyuki Yamada

  2. Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Jose A. Cancelas

  3. Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Jose A. Cancelas

  4. Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Marc E. Rothenberg

Authors
  1. Yoshiyuki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose A. Cancelas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc E. Rothenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiyuki Yamada .

Editor information

Editors and Affiliations

  1. Division of Applied Medicine, University of Aberdeen Institute of Medical Sciences, Aberdeen, United Kingdom

    Garry M. Walsh

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Yamada, Y., Cancelas, J.A., Rothenberg, M.E. (2014). Murine Models of Eosinophilic Leukemia: A Model of FIP1L1-PDGFRα Initiated Chronic Eosinophilic Leukemia/Systemic Mastocytosis. In: Walsh, G. (eds) Eosinophils. Methods in Molecular Biology, vol 1178. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1016-8_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1016-8_26

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1015-1

  • Online ISBN: 978-1-4939-1016-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation